29 Apr 2022
View the Factsheet: Invesco Global Focus Fund (UK)
Mapping the human genome
Emergence of the field is putting research and drug development into an exciting new path.
Changing medical outcomes
Diseases caused by genetic mutations can be diagnosed before they have even emerged.
Genetic research technologies
Businesses that are focused on technology much more predictable than drug development.
Mapping the genome can legitimately be thought of as a Big Bang moment in medicine. The Human Genome Project began in 1990, with a goal of mapping the full human genome by 2005. It was ultimately completed by 2003.
The emergence of the field of genomics put research, drug development and diagnostics on a new and exciting course. We are still in the early stages of this.
A key advancement has been the discovery that several of our most vexing and deadly diseases are caused by genetic mutations. This provides the opportunity to screen and diagnose long before any disease has even manifested.
DNA is an acronym that is often tossed about. It stands for deoxyribonucleic acid. Cutting to the chase, DNA is essentially the recipe for the production of the proteins in your body. Each of us has thousands of proteins in our body and those proteins play a variety of critical roles in human cells.
Genetic disorders are often the result of not having a particular protein, having too much of it or too little of it. Knowing this, clinical researchers can develop treatments to fixing protein-related issues that are causing disease.
Investing in companies engaged in gene-based drug development is hard to do. The payoff can be high, but even if you hit on a company with a breakthrough molecule the odds are against you.
Roughly 90% of drugs that enter clinical trials never reach a commercial stage. Development stage drug companies are well known for having huge price swings even when things are progressing well. In the event of a clinical setback, the first bid can be 50% less than it was just minutes before.
We have found that ideas focused on foundational enabling technologies in genetic research and drug development are better than investing in drug developers. As you’ve heard before, the general store selling picks and shovels made far more money than the average gold miner in the California Gold Rush of the mid-19th century. The same is true here.
There is a research advantage that can be garnered, we believe, and the businesses are much more predictable.
In our Invesco Global Focus Equity Fund, Illumina Inc is one we have liked for years and it is among the biggest players in genetic medicine. It is a US-based company that produces about 70% of the genetic sequencing systems at work in the world today. Those systems are used in academia, biotechnology, by drug developers and in diagnostic settings.
Entire companies are built on a foundation of Illumina systems and the world of medicine is moving rapidly towards them. The Covid-19 vaccines developed by Moderna Inc, Pfizer Inc, and others, were done in a remarkably short period of time after the virus was sequenced on an Illumina system.
Once Covid-19’s molecular traits were understood, the solution came quickly. Normally, the median time from clinical development to approval of a vaccine is 9.2 years.
DNA testing is already being used for several cancers. Genetic tests for several types of breast cancer, colon cancer and others are readily available today and widely used already. This is just the beginning.
Over the next several years screening will become available for the early detection of an increasing variety of cancers, well before patients have displayed any symptoms. Illumina will participate in that in a variety of ways.
Cancer, yearly, is the world’s second biggest cause of death and early detection of it will be both a big life saver, as well as a big money saver, as early treatment is far less costly to the world’s health systems.
Early detection of genetic markers will lead to early management of risk factors in diet, behaviour and treatment. Time is a huge advantage in treatment outcomes and early detection of genetic predisposition will give patients an unprecedented amount of time.
As the field of genomics and genetic medicine advances, for many of the most challenging health problems we have we will have more and more answers for. There are many ways that investors can participate and Illumina is one and we have other in the portfolio as well.
The history of drugs was rooted in chemical formulations, but the future is molecular and biological. Set against an aging world population, solutions will be required to address many of the diseases that grow in frequency as we age. Genomics and genetic medicine are going to play a big role in that.
Investment risks
The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.
The fund may invest in certain securities listed in China which can involve significant regulatory constraints that may affect the liquidity and/or the investment performance of the fund.
The fund invests in a limited number of holdings and is less diversified. This may result in large fluctuations in the value of the fund.
Important information
Data as at 31.03.2022, unless otherwise stated.
This is marketing material and not intended as a recommendation to buy or sell any particular asset class, security or strategy. Regulatory requirements that require impartiality of investment/investment strategy recommendations are therefore not applicable nor are any prohibitions to trade before publication.
Where individuals or the business have expressed opinions, they are based on current market conditions, they may differ from those of other investment professionals and are subject to change without notice.
For more information on our funds and the relevant risks, please refer to the share class-specific Key Investor Information Documents (available in local language), the Annual or Interim Reports, the Prospectus, and constituent documents, available from www.invesco.eu. A summary of investor rights is available in English from www.invescomanagementcompany.lu. The management company may terminate marketing arrangements. This is not an invitation to subscribe for shares in the fund and is by way of information only, it should not be considered financial advice. This does not constitute an offer or solicitation by anyone in any jurisdiction in which such an offer is not authorised or to any person to whom it is unlawful to make such an offer or solicitation. Persons interested in acquiring the fund should inform themselves as to (i) the legal requirements in the countries of their nationality, residence, ordinary residence or domicile; (ii) any foreign exchange controls and (iii) any relevant tax consequences. As with all investments, there are associated risks. This communication is by way of information only. Asset management services are provided by Invesco in accordance with appropriate local legislation and regulations. The fund is available only in jurisdictions where its promotion and sale is permitted. Not all share classes of this fund may be available for public sale in all jurisdictions and not all share classes are the same nor do they necessarily suit every investor. Fee structure and minimum investment levels may vary dependent on share class chosen. Please check the most recent version of the fund prospectus in relation to the criteria for the individual share classes and contact your local Invesco office for full details of the fund registration status in your jurisdiction. Please be advised that the information provided in this communication is referring to Invesco Global Focus Equity Fund Class A (accumulation - USD) exclusively. This fund is domiciled in Luxembourg.
Denmark: The fund is registered in Denmark for professional investors only and not for public distribution. Guernsey: The fund can only be promoted to Professional Clients. Isle of Man: The fund is an unregulated scheme that cannot be promoted to retail clients in the Isle of Man. The participants in the scheme will not be protected by any statutory compensation scheme. Israel: Issued by Invesco Asset Management Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH, UK. Authorised and regulated by the Financial Conduct Authority. No action has been taken or will be taken in Israel that would permit a public offering of the Fund or distribution of this communication to the public in Israel. This Fund has not been approved by the Israel Securities Authority (the ISA). Accordingly, the Fund shall only be sold in Israel to an investor of the type listed in the First Schedule to the Israeli Securities Law, 1968, which has confirmed in writing that it falls within one of the categories listed therein (accompanied by external confirmation where this is required under ISA guidelines), that it is aware of the implications of being considered such an investor and consents thereto, and further that the Fund is being purchased for its own account and not for the purpose of re-sale or distribution. This communication may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Nothing in this communication should be considered investment advice or investment marketing as defined in the Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 1995 (“the Investment Advice Law”). Investors are encouraged to seek competent investment advice from a locally licensed investment advisor prior to making any investment. Neither Invesco Ltd. Nor its subsidiaries are licensed under the Investment Advice Law, nor does it carry the insurance as required of a licensee thereunder. This communication does not constitute an offer to sell or solicitation of an offer to buy any securities or fund units other than the fund offered hereby, nor does it constitute an offer to sell to or solicitation of an offer to buy from any person or persons in any state or other jurisdiction in which such offer or solicitation would be unlawful, or in which the person making such offer or solicitation is not qualified to do so, or to a person or persons to whom it is unlawful to make such offer or solicitation. Jersey: Consent under the Control of Borrowing (Jersey) Order 1958 (the "COBO Order") has not been obtained for the circulation of this communication. The offer that is the subject of this communication may only be made in Jersey where it is valid in the United Kingdom.